SAB Biotherapeutics holds virtual R&D Day; reviews platform and recent designations

SAB Biotherapeutics, Inc.

Presented portfolio update including recent Breakthrough Therapy and Fast Track designations.
Highlighted programs: influenza, C. diff, type 1 diabetes (SAB-176, SAB-185, SAB-142, SAB-195).
No new financial guidance, clinical data, or material business changes disclosed.
Presentation furnished as Exhibit 99.1 but not text-available; summary based on filing narrative.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.